Quiescence in melanoma is not a rare and static state but a dynamic and reversible condition accessible to most tumor cells, ...

DelveInsight's, “Bladder Cancer Pipeline Insight 2025” report provides comprehensive insights about 80+ companies and 100+ ...

The cell cycle is regulated by cyclins, ... Phosphorylation by CDK-2-cyclin E complex prevents this inhibition and so progression from G1 to S phase can continue. Overall, ...

Applying the same approach (comparing Stator states’ expressed d-tuple genes and s2s-DEGs with known cell cycle phase marker genes) identified five less-populated states (#3-4, #6–8) as additional ...

PD-1/IL-2 α-bias bispecific antibody fusion protein IBI363 in patients with immunotherapy resistant advanced non-small cell lung cancer: results from a Phase 1 study Updated data on IBI363 monotherapy ...

This period coincides with the rising phase of solar cycle 25, which has shown itself to be more intense than the previous solar cycle. We derive satellite altitudes and velocities from TLE files and ...

On June 1, Allogene Therapeutics Inc. (NASDAQ:ALLO) presented updated data from the Phase 1 TRAVERSE study of ALLO-316 in advanced or metastatic renal cell carcinoma/RCC during an oral ...

Importantly, we did not observe the G1-phase marker accumulating in cells undergoing infection (Figure 4B–D and Figure 5–figure supplement 2A-C), favouring the hypothesis of a cell-cycle arrest and ...

Perelman School of Medicine have developed a dual-target CAR-T cell therapy that has slowed GBM tumor growth in nearly two-thirds of patients based on results from a Phase I clinical trial.

Kite Pharma’s bicistronic CAR T-cell therapy hit the main goal of a phase 1a trial, with zero dose-limiting toxicities (DLTs) occurring in patients with advanced B-cell lymphoma (BCL).

MIAMI--(BUSINESS WIRE)--Summit Therapeutics Inc. (NASDAQ: SMMT) (“Summit,” “we,” or the “Company”) today announced topline results from the Phase III clinical trial, HARMONi, the first ...

Diakonos Oncology Closes $20 Million Financing to Accelerate Phase 2 Glioblastoma Clinical Development Program and Expand Use of Innovative Dendritic Cell Platform for Studies in Other Indications.